#### **REMARKS**

Reconsideration is requested.

Claims 1-74, 76-78 and 80 have been canceled, without prejudice, to advance prosecution.

The recitation of the claimed complements have been revised to recite the specific sequences, and claim 81 has been amended to recite the specific sequences which were part of the claims from which the unamended claim depended. Claims 86 and 87 have been amended to further identify the recited type- and subtype-specific amino acid residues. Claims 86 and 87 recite the inclusion of at least 12 contiguous nucleotides, which finds support, for example, at page 8, line 2, of the specification. No new matter has been added. The amendments are not believed to raise new issues requiring further search and/or consideration. New claims have not been added. Entry of the claims will, at a minimum, reduce the issues for appeal, as described below. Entry of the amendments is requested.

The Examiner is again requested to return a completely initialed copy of page 1 of PTO 1449 Forms which were filed May 4, 2001, and of which a partially initialed copy was received with the Office Action of October 6, 2003. Specifically, the Examiner has executed the entirety of the Form and included her initials in the column to the left of the listed "U.S. Patent Documents" and "Foreign Patent Documents". The Examiner has not however included her initials in the left column next to the listed "Other Documents". The applicants last made a similar request on September 2, 2004 and included a copy of the previously-received PTO 1449 Form for the Examiner's information. Return of a completely initialed copy of the PTO 1449 Form is requested.

- 12 -

Claims 75, 79 and 81-87 are pending. Upon entry of the present Amendment, claims 75, 79, and 81-87 will be pending.

The Section 112, second paragraph, rejection of Claims 75, 79 and 81-87 is obviated by the above amendments. Entry of the present Amendment will, at a minimum, reduce this issue for appeal. The amended claims do not refer to the previously objected-to "at least 5 nucleotide" although the applicants believe the unamended claims are definite in this regard. Moreover, the claims have been amended to refer to "the" complement of specific sequences, which is believed to obviate the Examiner's concerns regarding the recitations of complements in the unamended claims.

The Examiner is urged to appreciate that the nucleotides encoding the amino acids recited in claim 86 and 87 are not "random ... polynucleotide primers" as suggested by the Examiner on page 2 of the Office Action dated April 11, 2005. Rather, the recited amino acids were identified as amino acids unique to the claimed HCV sequences and which are not present in any of the amino acid sequences identified prior to the filing of the priority application. The identification of the recited amino acids involved alignment of multiple HCV amino acid sequences, including sequences of the art, and screening for amino acids present in the HCV sequences of the present invention but not present in prior published HCV sequences. See, Figures 2, 4 and 6 of the present application.

The recited "12 contiguous nucleotides" will be understood by one of ordinary skill in the art to require, regardless of the reading frame, a fragment of at least 3 consecutive amino acid sequences, of which there is one of those specified in claims 86

and 87. The remaining nucleotides encoding the additional at least 2 amino acids are also not random as they are (i) part of a sequence encoding a HCV polyprotein and (ii) occur at a specified position in the HCV sequence relative to the sequence encoding the amino acid specified in claims 86 and 87 (i.e., at least 12 contiguous nucleotides).

The at least 3 (and up to at least 4) amino acids encoded by the polynucleic acids of claims 86 and 87 are necessarily encoding a part of at least 3 (and up to at least 4) consecutive amino acids of an HCV polyprotein of which at least 1 amino acid is unique to the HCV type or subtype as specified in claims 86 and 87. There is the possibility of 2 consecutive or non-consecutive amino acids unique to a given HCV type or subtype in the same fragment, e.g., V2652 and Q2653 for HCV type 7, or Q2752 and D2754 of HCV type 11.

The claims are submitted to be definite. Entry of the above and withdrawal of the Section 112, second paragraph, rejection of claims 75, 79 and 86-87 are requested.

The Section 112, first paragraph "written description", rejection of claims 86 and 87 "and claims 81-85 in as far as they read on [sic, depend from ?] claims 86 and 87" is obviated by the above amendments which have been made in response to the Examiner's statement on page 3 of the Office Action dated April 11, 2005, that "Claims directed to these specific SEQ ID NO's [SEQ ID NO: 1, 3, 5 etc. odd numbers to 105, and sequences encoding SEQ ID NO:107-207 which correspond to specific portions of HCV genomic sequences that fall within certain subtypes] would meet the written description provisions of 35 USC 112, first paragraph." Moreover, as the Examiner has apparently based, at least in part, the Section 112, first paragraph, rejection on the alleged indefiniteness of claims 86 and 87 (see, page 2, last paragraph, of the Office

Action dated April 11, 2005), and the Section 112, second paragraph, rejection has been obviated by the above, withdrawal of the Section 112, first paragraph, rejection is requested.

Entry of the present Amendment and withdrawal of Section 112, first paragraph "written description", rejection of claims 81-87 are requested.

The Section 102 rejection of claims 81-87 over Houghton (U.S. Patent No. 5,350,671) is obviated by the above amendments. The amended claims do not refer to the "short polynucleotide sequences" which are believed to have been the basis for the rejection. See, page 3 of the Office Action dated April 11, 2005.

Attached is a 24 page comparison of relevant parts of the sequence of Figure 66 of the cited Houghton et al reference as compared with Figures 2, 4 and 6 of the present application. The attached further illustrates that the sequence of Houghton et al is identical to the HCV sequence occurring on top of each of the applicants sequence alignments. The Examiner will also appreciate that for the NS5B region, the amino acid numbering of Houghton et al differs with 1 integer from the amino acid numbering in Figure 6 of the present application. That is, for example, in claim 86, S2645 is listed as an amino acid unique to type 7, whereas the closest S in the NS5B sequence is Houghton is at position 2646. The numbering of the claims has been clarified by reference to Figures 2, 4 and 6.

Entry of the present Amendment and withdrawal of the Section 102 rejection are requested.

Maertens et al Appl. No. 08/836,075 Monday, June 11, 2005

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned in the event anything further is required in this regard.

Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

By:

Reg. No. 36,663

BJS:

901 North Glebe Road, 11th Floor

Arlington, VA 22203

Telephone: (703) 816-4000 Facsimile: (703) 816-4100



FIG.66A

STATE OF THE PARTY	L	R T MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATR
HCV1 HCV-J	1a 1b	MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATR
BNL1 BNL2 CAM1078	1d 1d	R-TXXXXXXXXX
FR2	le 1f	A-
нсј6	2a	R-T
HCJ8 CH610	- 2b 2c	R-T
NE92 BNL3	2d 2e	
FR4	2f	R-TP-
HCVTR	3b	LRQTLNVV-
DK13 CAM600	4d 4e	R-TM
GB809 BNL7	4e 4k	L-R-TM
BE95	5a	R-TM
нк2	6a	LR-TT
FR1	7a	LR-TM
VN4 VN13	8a 8b	LR-TI
VN12	9a	LR-TM
NE98	10a	LR-TXVVV-

HCV1	_	7 7 7 	and the second of the second o
HCV1	Figure 2 -	· concrui	*TSFRSOPRGRROPIPKARRPEGRIWAQPGYPWPLYGNEGCGWAGHLLSI TOO
HCV-J 1b		· · L	
HCV-J 1b			THE CAP CAP CAR OP I PKAR PEGRTWAQPGY PWPLYGNEGCGWAGWILLS I
BNL1 1d	HCV1		
BNL1 1d	HCV-J		x_xsx
CAM1078       1e			OSD-XXH
CAM1078		1d	
HCJ6 2a	CAM1078	1e '	AA
HCJ6 2a		1f	
HCJ6	I VS		om vo_cv
HCJ8 2b	2076	. 2a	
NE92 2d			DST_KS_GR
NE92 2d			D_TT-KS-GR
BNL3			
BNL3       2f      DAT-KS-GR         HCVTR       3b      KQ-HLSRS			D_0\n'====================================
HCVTR 3b	BNL3		LD-AT-KS-GRLL
DK13	FR4	21	
DK13			VO_HISRSKКL
CAM600 4e	HCVTR	3b	
CAM600 4e			SS
GB809 4e	DK13	4d	
GB809       4e         BNL7       4k         BE95       5a         HK2       6a         FR1       7a         VN4       8a         VN13       8b         VN12       9a		4e	
BNL7 4K  BE95 5aQ-TS-GAL  HK2 6aV-Q-TS-G  VN4 8aV-HQT  VN13 8bV-QNQ  VN12 9aAV-QNQ		4e	X
BE95 5aQ-TS-GAL		4 k	
HK2 6a	DIATE 1	• • •	C C1
HK2 6a	2205	5a	Q-TS-G
FR1 7aV-Q-TS-G	BEAD	34	
FR1 7aV-Q-TS-G		6-	Q_Q_H
VN4 8aV-HQT	HK2	ba	
VN4 8aV-HQT		<b>~</b>	V-Q-TS-G
VN13 8bV-HQT	FR1	/a	
VN13 8bV-HQT	•	2	V-HOT
VN12 9aA	VN4		V_HOT
VN12 9aA	VN13	<b>48</b>	
VN12	•••-	•	V_0NO
	VN12	9a	A
NEGR 10aSKTS	, ATEM		n mC
	NE98	10a	SK13

10a

NE98

Figure 2 ~	· conti	23/74
		RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA
HCV1 HCV-J BNL1 BNL2 FR2	1a 1b 1d 1d 1f	101 150 RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARANNS-T
HC-J6 HC-J8 CH610 NE92 BNL3 FR4	2a 2b 2c 2d 2e 2f	NHV
HCV-TR	3b	vv
GB116 DK13 CAM600 GB809 G22 GB549 GB438 BNL7	4c 4d 4e 4f 4g 4h 4k	N
BE95	5 <b>a</b> .	NNKG-IV
HK2	6a	HNV
FŘ1	7a	NNVL-GVL-GV-A-
VN4 VN13	8a 8b	NNXXXIE
VN12	9a	D-X-NXV-AE

$\sim$		_	÷
•	•	 7	

	• •	
Figure 2	e - conti	I AUCURUI ENCUMVATOM ROCCES
		LAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL-200
HCV1	1a `	131
HCV-J	1b	LAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL
BNL1	1d	
BNL2	1d	XT-HEAS-V
FR2	îf	-XXGXXXXXXXXXTT-HEAS-V
		A AG -AAAAA-AAAAAXE-HST-DG
HC-J6	2a	FI-T-VAE-K-ISTG
HC-J8	2b	
CH610	2c`	
NE92	2d	
BNL3	2e	X
FR4	2f	
BNL4	2g	
BNL5	2h	
BNL6	2i	IIVK-TSHS
HCV-TR	3b	A-GFFCGLEYT-TS
GB116	4c	-EAVISTVNYAS-V
DK13	4d	TVNYAS-V
CAM600	4e	AVITVNYAS-I
GB809	4e	AVI
G22	4f	GVNYAS-V.
GB549	4 q	AVI
GB438	4h	QHYIS-I
BNL7	4 k	-I-FINYVS-I
BNL8	4 k	IINYTS-I
BNL9	4 k	IINYTS-I
BNL9	4 k	IIXXTNYVS-I
BNL10	4 k	IX
BNL11	41	II
		• • • • • • • • • • • • • • • • • • • •
BE95	5a	
HK2	6a	AII
FR1	7a	AIK-AS-I
VN4	8a	XXIXX-X-X-X-XXTAHYT-KS
VN12	9a	-XAIIXTINYA-KS
NE98	10a	I-FFFLT-TAGLEYAS

Figure :	2 - cont	inued
		YHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRD
*****	_	
HCV-1	1a	YHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRD
HCV-J	1b	
BNL1	1d	
BNL2	ld	
FR2	1f	S-GK-IXIPLL-A-I
	_	
HC-J6	2a	-MT-DTWQLQA-VVEKVTIPVS-NVQQ
HC-J8	. 2b	
CH610	2c	-MSWQLEG-VEQIPVS-NI-Q
NE92	2d	-MQWQLRVVEEKIIPVS-NI-VSQ
BNL3	2e.	
FR4	2f	-MAA-DWOLRVVE-SSGRFHIPIS-NI-VSK -MAS-NIWOMOC-VV
BNL4	2g	
BNL5	2h	-MSWQLKVVE-HQ-QIPVNVSQ
BNL6	2i	-MIPVNVSQ
HCVTR	3b ,	-VLS-GE-VLTTQ-STTVSTV-T
	,	Z V E Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
GB116	. 4c	I
DK13	<b>4</b> d	
CAM600	4e .	
GB809	4e -	
G22	4f	
GB549	4g	
GB438	4h	
BNL7	4 k	
BNL8	4 k	
BNL9	4 k	
BNL9	4 k	
BNL10	· 4k	
BNL11	41	
GB724	4×	I
		TEMM TPVAVS
BE95	5a -	
•		QILSAPS
HK2	6a	LLDAMLVDDR-TH-VL-IPN
		DAML-IPN
FR1	7a	LS-NFETMLIKAELPVSL-VPN
VN4	8a	L
		LQASL-VPN
VN12	9a	LNGMLKTLTKLSASL-VQN
		MGTLTKLSASL-VON
NE98	10a	-MS-GG-ILSTIPVSXVKS
	_	G-1IPVSXVKC

Figure 2	- conti	GKLPATQLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWT-300
	•	251 300
HCV-1	1a	GKLPATOLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWT-
HCV-J	1b	SSI-T-TIVA-AMSYE-
BNL1	īd	ASV-TXAIVXX-FMXAM-H-
BNL2	1d	ANV-TAAIVT-AFRMLYH-
FR2	1f	ANA-IDEVVA-VFM-IGTS
HC-J6	2a	PGALTQGTMV-MG-M-AA-M-IVQHF
HC-J8	2b	RGALTRST-V-MI-MAAVA-MILS-A-MVQNF
CH610	2c	PGTLTKGA-V-VI-MVALMIAA-AVIAQTF
NE92	2d	PGALTKGTTIIAFIA-M-AS-V-IIQH-KF
BNL3	2 <b>e</b>	PGALTKGARAV-MVA-MIAA-A-IVA-KYF
FR4	2f	PGALTRGATI-MIA-MIAA-VAVVQY-TF
BNL4	2g	PGALTRGTTI-MVIVA-MIAA-VVIVQH-NF
BNL5	2ĥ	PGALTRGTTI-AVFA-MS-F-MIQH-IF
BNL6	<b>2</b> i	PGAXTKGTII-AF
HCVTR	3b	LGVTTASI-T-V-MARQAF-AAF-AT-
GB116	4 C	VGA-LESS-VMAVIGM-S-Q
DK13	4d	LNA-LESVMGIVGQ
CAM600	4e	AGA-LEPVMAMIGLMQ
GB809	4e	VGA-LEPVMAVGLMQ
G22	4f	LGA-LESMV-M-TGI-A-MR-L
GB549	4 a	VGA-LESMVMAVIGMR
GB438	4h	LGA-L-SV-Q-V-M-AIHGAMVS-Q
BNL7	· 4k	IGA-LESS-VMAVIX-XGLM-S-R
BNL8	4 k	IGA-LESS-VMAVIGLM-S-R
BNL9	4 k	IGA-LESS-VMAVIGAM-S-R
BNL9	4 k	TAA-LESS-VMAVI-XGLM-SXQ
BNL10	4 k	IGA-LESS-V-VMAVIGLM-S-R
BNL11	41	LSA-LMSVVMASGAMQ
GB724	4×	VDA-LESFVMAVGAMQ
BE95	5a	LGAVTAPAV-Y-A-G-AAALMYRQ-A-
HK2	. 6a	ASTGFVA-A-VVSILAQ
FR1	7a	SSV-IHGFVA-AFM-IIIR-KY-QV
VN4	8a	AST-V-GF-K-V-IMA-AFMGLLRM-QV
VN12	9a	ASVSIRGV-E-VA-AFMGLRMYEI
NE98	10a	PCAATAST-V-MM-XAALXG-SWRH-Q

		37/74
•	T	TOGCNESIYPGHITGHRMAWDMMMNWSPTTALVMAQLLRIPQAILDMIAG
Figure 2 -	contin	TOGENESTYPGHITGHRMAWDMMMNWSPITALYMAGLERITGHT
- •	7	301
		TOGCNCSIYPGHITGHRMA
HCV-1	1a	V-DVS
HCV-J	1b	E
BNL1	1d	<del>-</del>
BNL2	1d	V-DSXXX
FR2	1f	V-DS
	_	V-DT
HC-J6	2a	EQ
HC-J8	2b	V-EX
CH610	2c	V-E
NE92	2d	V-D
BNL3	2e	V-EX
FR4	2f	V-EX
BNL4	2g	S-D
BNL5	2h	V-D
D11.20		
HCVTR	3b	V-TVS
2.0		DAV
GB116	4c	DT
DK13	4d	DT
CAM600	4e	DA
GB809	4e	D
G22	4f	ED
GB549	4g	DD
GB438	4h	DV
BNL7	4 k	D
BNL8	4 k	A-D
BNL9	4 k	D
BNL9	4 k	D
BNL10	4 k	E
BNL11	41	V-D
GB724	4x	DT
GD 123		a 17
BE95	5a	V-NSV
BEJJ		m V
HK2	6a	V-DTV
пка		
FR1	7a	DXNXV
I.V.T		<u>_</u>
VN4	8a	V-ET
A 14.4		
17311 2	9a	A-DA
VN12		
NE98	10a	V-D
NESO		·

, A SHEFT (BILLE 26)	ľ
FR4 FR13 EB1 NZL1 NZL1 HCV-TR GB358 DK13 CAM600 GB809 HPCCOREZB HPCCOREZB HPCCOREZC GB724 BNL7 BE95 HK2 VN13 VN4 VN12 FR1 NE98 FR19	Isolate HCV-1 HCV-1 BNL1 BNL2 CAM1078 FR2 FR16 HC-J6 HC-J6 HC-J8 CH610 NE92 BNL3
11001111111111111111111111111111111111	
18 76 76 28 28 46 46 46 46 47 48	SEQ   SEQ   ID   M   M   M   M   M   M   M   M   M
-R-T	FIG.66A  MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATR  MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATR

																•			•																
KTSERSOPRGRROPIPKARRPEGRIWAGPGYPWPLYGNEGCGWAGWLLSP-100	51 core-V	KTSERSOPRGRROPI PKARRPEGRTWAQPGYPWPLYGNEGCGWAGWLLSP	į (   	V		X		WWSSS	TT				D-XATS-GR	KS-	X-QLD-XTT-KS-GRLL		8	1				! !	l l	   	1			1			1 1 1 1	ONO-	V-Q-T-V	 	·[]
SEO	, E		. (	7		10/6	12	99					14	18	9/							(	28					٠		46	44	48	42	20	104
9 C N	) 1	ლ	្ត ភូរ	p	7 T	1e	1£	19	2a	2b	2c	2d	2e	2£	2k	3a	3 <b>a</b>	39	4c	40		4 e	ਰਾ '	4.	4.	<b>T</b>			6a	7a				٦,	
ראן די ריסין מידיגין		HCV-1		BNLI	BNL2	CAM1078	FR2	FR16	HCJ6	HCJ8	CH610	NE92			FR13					٠			BNL7		HPCCOREZB	HPCCOREZC	GB724:	BE95	HK2	VN13	VN4	VN12	FR1	NE98	FR19
													SI	JB	STI	TU	ITE	SI	IEE	T:	(RU	ILE	26	5)					•			•			

	٠.							•									
RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA	150 RGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARA	N	L-SXX09	ASH	T $$ T $$ H $-$ H	X	\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\	\	^	^XXXXXXXX	^	^	N	A	-X-AXNXXXXXXXXXX-XX-X	Λ	) ) 
SEO	OH.	(4)	10/	99		14/	18 76						2.8		46	4. Q	50
Tvbe	12 a	g p	1 H F	י המ מסי	2b 2c	2d 2e	() () 귀 국		4 4 0 0	4	4 4 H 0	<u>4</u> 4 Ծ Մ	수	დ დ 9	7 a	7 D	9a 10a
Isolate	HCV1	HCV-J BNL1	CAM1078	FR16 HC-J6			CLIT FR4						BNL7	BE95 HK2	VN13	VN4 VN12	FR1 NE98
				•													


LAHGVRYLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL-200	1	LAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGL	AS-	ETXGXXXXXXXGXXXGXG	Q-F-D- T-R-K-ISTG	VIS		SSL-WLD-VIIII	1	MUSU-X777	VK	V	TNXI-XIIAX-I/SSIIII	XXX	EHY	1	V-RTTRRTTR	-XHI	ľ	\-CI\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\	I	IVHYH	I-SI-HXHA	IQHY IQHY	I-SAANI	H	I-SAXNIXXII
·	SEO		4η α	15	99				16	λ Σ	2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	56	97								•				30	ე წ 2 4	36
	Туре	1a 1b	197	7 <del>41</del> 7	, 19	0 C7	0 0 7 6	7 7 7	64 c	H C	2,4 2,4	2;	2 2 2 3	a S	4 e	4a	4 4 O n		4°C	4. 4. D. 0		4.4		4.4 T	4. 7.	4. 4. X X	4 k
	Isolate	HCV1 HCV-J	BNL1 BNL2	FR2	FR16 HC16	HC-18	CH610 S83	NE92	BNL3		BNE 5	BNIL6	ER13	HCV-TR	24		726) 21 21180	GB215	GB358	CAMEOO	GB809-2	CAMG22	CAMG27	GB438	BNL7	BNL9 BNL9	BNL10

IX	I-SVYNT	1	-TAHYT-KS -TINYA-KS -TIK-AS-I IT-TAGLEYAS
AI	XXX	AII	AII

33 444 52 52

4k 41 5a 5a 6a 7c 7d 9a 10a

BNL11 BNL12 BE95 BE100 HK2 VN4 VN12 FR1 NE98




41 40
41 68 70 70 99 99

BNL12 GB724 BE95 BE100 HK2 VN4 VN12 FR1

·																																		
GKLPATQLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWT-300	251 7300	PATQLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHW -T-TTVA-AMSSYE	XX-FMXA	VT-AFRM	VA-VFM-I	W-MI	RGALTRST-V-MI-MAAVA-MILS-A-MVQNF DCTI-TRGA-V-VI-MVAIMIAA-AVIAOTF	A II-MVAIM-AA-VVVVOH-	TTIIAFI	-ARAV-MVA-MIAA-A-IVA-K-	ATI-MIA-MIAA-VAVV	TTI-MV-WIMVIAA-VVIV	i H EH E	!   	I-MII		-^-E	PGA-LESFVMA	VMAG	S-VMAVIG	9IA	S-VMAAI	DVIDMV		GI		I9I		Q-VMAMAMMMMA	-S-VMAVIX-X6L	S-VMAV	S-VMAVIIGA		IGA-LESS-V-VMAVIGL
	SEQ	7	4	ထ	12			•		16	18	20	2,4	7 L	9														1	30	32	46	36	r R
	Туре	1a 17	ng 1	1q	1£	2a	, ty	) (	р 10	<b>5e</b>	S£	2g	2h	ל 2	7 C	ა გ ჯ	α. Υ	4, 4 Q u	4 4 4	4 D	4 0	4c	4q	. 4e	4e	4£	4 £	<u>4</u> g	4h	4 k	4. 7.	4. X.	4. X.	4 K
	Isolate	HCV-1	BNL1	BNL2	FR2	HC-J6	HC-J8	01010 083	NE92						E FRIS		•	J. 24	600091		_	GB358	DK13	CAM600	GB809-2	CAMG22	CAMG27	GB549	GB438	BNL7	BNL8	BNL9	BNL10	BNL11

V V V V V V V V V V V V V V V V V V V	VS TACKING TO THE TOTAL THE WAS INVESTIGATED THE VITABLE KIT FUAL ED THE TACKING TO THE VITABLE KIT FUAL ED THE VITABLE FUAL ED THE VITABLE KIT FUAL ED THE VITABLE KIT FUAL ED THE VITABLE FUAL FUAL ED THE VITABLE FUAL ED THE VITABLE FUAL ED THE VITABLE FUAL FUAL ED THE VITABLE FUAL ED THE VITABLE FUAL ED THE VITABLE FUAL FUAL FUAL FUAL FUAL FUAL FUAL FUAL	301 319	V-D			V-DSXXX	·V-DTT		V-EX	V-E	V-E	V-E	S-D	V-D	V-DX	. !	1	-L		DVS	DAV	D			D	DA	BB		DD	DV		A-D	1-1-1-0-1	D		V-D
	SEQ	Q I		<b>ታ</b>	<del>ه</del> (	12					16	18	20	24	92																0	0	34	، ب	œ (	· 
	Туре	Ta	1p	1d	1d	H (	, א ק	ا 5 ر	יז ני יז גי	א קי	, e	2£	2g	5h	2,k	3а	3p	4a	4a	<b>4</b> p	A.	ტ.	Δ, 4 Ο 4	ğ,	4e	Δ, 4 Φ, 4	4. H	4 £	<b>4</b> .0	4p		۸.		4k	X.	5 T.
	Isolate	HCV-1	HCV-J	BNL1	BNL2	F R C	80111H	CH610	883	NE92	S BNL3	BR4	ST BNL4	TI BNI'S	TR13	S BR36	HCVIR	ET .	S) GBBUS-4	70 21 2011	97785 E 2	6)	68338 0813	00000	CAMBOU	SERCO SCINE				5B4 38		BNLB		Э г	BINLLL	DINTITO



444 522 523

44 x 5 a 6 a 7 c 7 c 1 0 a 1 0 a 1

GB724 BE95 BE100 HK2 VN4 VN12 FR1


•					
FIG.66B	763				·
CVQPEKGGRKPARLIVFDLGVRVCEKMALYDVVT-2600 SPGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTE	2645 STVTBS	N	XX	PEE-T-HMI PET-H	이
IMAKNEVFO	Type SEQ ID Ia	526.4	<i>0</i>	70 72 74 78	80 80
P A V	Φ	9	0		33333 33333 3435 355 355 355 355 355 355
VIPI KLPL Figure	Isolate HCV-1	2TY4 BNL1 BNL2 FR17	FR2 FR16 HC-J	ARGB NE 32 BNI 3 BNI 3 ER 13 ER 13	(92 anna) 133 (92 anna) 133 (93 anna) 133 (94 anna) 133 (94 anna) 133

88 88 88 88 88 88 88 88 88 88 88 88 88	
0.00	
GB48 GB116 GB215 GB215 GB215 GB358 GB358 GB358 GB3438 CAR1/1205 GB438 GB438 CAR1/501 EG13 BNL12 EG81 BNL12 EG81 BNL12 EG81 EG81 EG81 EG81 FR15 FR15 FR15 FR15	<u>.</u>
SUBSTITUTE SHEET (RULE 26	[د

YRRCR-2700 ACOE ASGVETTSCGNTETCYTKARAACRAAGEODCTMI VEGDDI VVICE	YRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICE							K		1	N		-IK	-IK	÷.	I		ITA	ITAKRSPDF	NPDF		PSF	
SEQ	I		54	56	58	29	64	89					70	72	74	78	80	-				. 28	
Type	rg.	ο Γ Ο Ε	ק ק	19	1q	1e	l£	1g	2a	5p	2 2 2	5d	2e	2.£	5h	2k	21	3a	3a	3a	3p	3g	
Isolate	HCV-1	おこく - C	BNL1	BNL2	FR11	CAM1078	FR2	FR16	HC-J6	HC-78	ARG8				II BNIS							F PAK64	26)

A-	A-	A	-W	-W	-W	 	- ¥	 	n		-W	-W	- <b>A-</b>			) c						 	)	
ISIK	XR			- TT-							i	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	W					PMIFI	FTKTK	IMKK	TM	EIMKIVPV		
! ! !		1	1	!	0	-  -	I	0	i !	1	1	1	1	1	1		1	0			1	1		
										84	98	88			90	35	94	96	98	100	102	106		
24 O	4. 4. O O	4 0	4e	4£	49	4ħ	0541	)1 4j	4.0	4 k	47	4m	<u>5</u> а	<u>5</u> а	7a	7c	7d	9a	10a	11a	11a	11a		
GB48	GB215	GB358	GB809	CAMG22	GB549	GB438	CAR4/12054	CAR1/50	EG13	BNL8	BNL12	EG81	BE95	CHR18	VN13	VN4	VN12	FR1	NE98	FR14	FR15	FR19		
										- · ·			S	UB	ST	TI	UTI	E S	HE	ΕT	(F	RUL	E 2	(6)

			1 d d d d d d d d d d d d d d d d d d d
			EDAASI RAFTFAMTRYSAPPGDPOPEYDLELITSCSSNVSVAHDGAGVP
Isolate	Type	SEO 1	
	•		2745 2757
HCV-1	1a		SAGVOEDAASLRA
HCV-J	1b	•	T
BE90	1p		Λ
BNL1	1q	54	NE
BNL2	1q	26	EΛ
FR17	1q	58	-XENV
CAM1078	Je	29	-N-TT-N-
FR2	1£	64	IE-XXPS
FR16	$^{1g}$	89	
HC-J6	, e		-Q-TEERN
HC-78	SP		-Q-NEERN
NE92	2d		-Q-TEERN
	2e	70	-QEDRN-
	2£	72	-Q-AEERNV
	Sh	74	-Q-TEERNV
	2k	78	-Q-TER-ENNP
	21	80	-Q-TEERNV
	3a		
	3a		1.
	3a		
	3p		-CER-A
	<u>3</u> g	82	-CX-D-EDRAALR
E 26			
5)			



```
GB48
GB116
GB116
GB116
GB215
GB215
GB215
GB358
GB809
GB809
GB809
GB809
GB809
GB849
GB840
G
```

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
Π

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.